blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3379934

EP3379934 - METHODS AND COMPOSITIONS FOR IDENTIFYING SUBJECTS AT RISK FOR CHECKPOINT BLOCKADE THERAPY ASSOCIATED COLITIS [Right-click to bookmark this link]
Former [2018/40]METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING SUBJECTS AT RISK FOR CHECKPOINT BLOCKADE THERAPY ASSOCIATED COLITIS
[2023/48]
StatusThe patent has been granted
Status updated on  29.03.2024
Database last updated on 13.07.2024
FormerGrant of patent is intended
Status updated on  23.11.2023
FormerExamination is in progress
Status updated on  19.03.2021
FormerRequest for examination was made
Status updated on  31.08.2018
FormerThe international publication has been made
Status updated on  02.06.2017
Most recent event   Tooltip29.03.2024(Expected) grantpublished on 01.05.2024  [2024/18]
Applicant(s)For all designated states
Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York, NY 10065 / US
[2018/40]
Inventor(s)01 / PAMER, Eric
24 Fairfield Street
Montclair, NJ 07042-4136 / US
02 / WOLCHOK, Jedd, D.
333 East 30th Street
Apt. 17C
New York, NY 10016 / US
03 / DUBIN, Krista
1230 York Avenue
Box 44
New York, NY 10065 / US
 [2018/40]
Representative(s)Barker Brettell LLP
100 Hagley Road
Edgbaston
Birmingham B16 8QQ / GB
[2018/40]
Application number, filing date16869244.023.11.2016
[2018/40]
WO2016US63530
Priority number, dateUS201562259445P24.11.2015         Original published format: US 201562259445 P
[2018/40]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017091694
Date:01.06.2017
Language:EN
[2017/22]
Type: A1 Application with search report 
No.:EP3379934
Date:03.10.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 01.06.2017 takes the place of the publication of the European patent application.
[2018/40]
Type: B1 Patent specification 
No.:EP3379934
Date:01.05.2024
Language:EN
[2024/18]
Search report(s)International search report - published on:US01.06.2017
(Supplementary) European search report - dispatched on:EP17.05.2019
ClassificationIPC:A01N63/00, A01N65/00, A61B5/00, A61K9/00, A61K35/66, A61K35/74, A61P1/00, A61K35/742, G01N33/569, A23L5/00, A61K45/06
[2019/24]
CPC:
A61K35/742 (EP,US); A23L5/00 (EP,US); A61K45/06 (EP,US);
A61K9/0031 (US); A61K9/0043 (US); A61K9/0053 (US);
A61P1/00 (EP,US); G01N33/56911 (EP,US); A61K2035/115 (US);
G01N2800/067 (EP,US) (-)
Former IPC [2018/40]A01N63/00, A01N65/00, A61B5/00, A61K9/00, A61K35/66, A61K35/74
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/40]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:VERFAHREN UND ZUSAMMENSETZUNGEN ZUR IDENTIFIZIERUNG VON PATIENTEN MIT RISIKO ZUR COLITIS IM ZUSAMMENHANG MIT CHECKPOINT-BLOCKADE-THERAPIE[2023/48]
English:METHODS AND COMPOSITIONS FOR IDENTIFYING SUBJECTS AT RISK FOR CHECKPOINT BLOCKADE THERAPY ASSOCIATED COLITIS[2023/48]
French:MÉTHODES ET COMPOSITIONS POUR L'IDENTIFICATION DE SUJETS À RISQUE DE DÉVELOPPER UNE COLITE ASSOCIÉE À UNE THÉRAPIE DE BLOCAGE DE POINTS DE CONTRÔLE[2023/48]
Former [2018/40]VERFAHREN UND ZUSAMMENSETZUNGEN ZUR IDENTIFIZIERUNG UND BEHANDLUNG VON PATIENTEN MIT RISIKO ZUR COLITIS IM ZUSAMMENHANG MIT CHECKPOINT-BLOCKADE-THERAPIE
Former [2018/40]METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING SUBJECTS AT RISK FOR CHECKPOINT BLOCKADE THERAPY ASSOCIATED COLITIS
Former [2018/40]MÉTHODES ET COMPOSITIONS POUR L'IDENTIFICATION ET LE TRAITEMENT DE SUJETS À RISQUE DE DÉVELOPPER UNE COLITE ASSOCIÉE À UNE THÉRAPIE DE BLOCAGE DE POINTS DE CONTRÔLE
Entry into regional phase01.06.2018National basic fee paid 
01.06.2018Search fee paid 
01.06.2018Designation fee(s) paid 
01.06.2018Examination fee paid 
Examination procedure19.07.2017Request for preliminary examination filed
International Preliminary Examining Authority: US
01.06.2018Examination requested  [2018/40]
01.06.2018Date on which the examining division has become responsible
13.12.2019Amendment by applicant (claims and/or description)
22.03.2021Despatch of a communication from the examining division (Time limit: M06)
01.10.2021Reply to a communication from the examining division
12.05.2022Despatch of a communication from the examining division (Time limit: M04)
22.09.2022Reply to a communication from the examining division
16.08.2023Despatch of a communication from the examining division (Time limit: M02)
18.10.2023Reply to a communication from the examining division
24.11.2023Communication of intention to grant the patent
22.03.2024Fee for grant paid
22.03.2024Fee for publishing/printing paid
22.03.2024Receipt of the translation of the claim(s)
Fees paidRenewal fee
14.11.2018Renewal fee patent year 03
14.11.2019Renewal fee patent year 04
13.11.2020Renewal fee patent year 05
30.11.2021Renewal fee patent year 06
13.10.2022Renewal fee patent year 07
29.09.2023Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]WO2013175038  (CONSEJO SUPERIOR INVESTIGACION [ES]) [X] 1,3-6 * the whole document *;
 [X]  - PAOLA GAUFFIN CANO ET AL, "Bacteroides uniformis CECT 7771 Ameliorates Metabolic and Immunological Dysfunction in Mice with High-Fat-Diet Induced Obesity", PLOS ONE, (20120726), vol. 7, no. 7, doi:10.1371/journal.pone.0041079, page e41079, XP055233593 [X] 1,3-6 * the whole document *

DOI:   http://dx.doi.org/10.1371/journal.pone.0041079
 [A]  - GUPTA A ET AL, "Systematic review: colitis associated with anti-CTLA-4 therapy.", ALIMENTARY PHARMACOLOGY & THERAPEUTICS AUG 2015, (201508), vol. 42, no. 4, ISSN 1365-2036, pages 406 - 417, XP002790922 [A] 1-13 * the whole document *

DOI:   http://dx.doi.org/10.1111/apt.13281
 [XP]  - KRISTA DUBIN ET AL, "Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis", NATURE COMMUNICATIONS, (20160202), vol. 7, no. 1, doi:10.1038/ncomms10391, pages 1 - 8, XP055563360 [XP] 2 * the whole document *

DOI:   http://dx.doi.org/10.1038/ncomms10391
 [A]  - SUGITA H ET AL, "THE VITAMIN B-12-PRODUCING ABILITY OF THE INTESTINAL MICROFLORA OF FRESHWATER FISH", AQUACULTURE, (1991), vol. 92, no. 2-3, ISSN 0044-8486, pages 267 - 276, XP002790923 [A] 1-13 * the whole document *

DOI:   http://dx.doi.org/10.1016/0044-8486(91)90028-6
International search[Y]WO2014082050  (SERES HEALTH INC [US]) [Y] 21* entire document *;
 [XY]US2015238544  (JONES LEE A [US], et al) [X] 1-4 * entire document * [Y] 5-11, 19, 20;
 [Y]WO2015166492  (YEDA RES & DEV [IL]) [Y] 18-25, 29-35, 40, 43 * entire document *;
 [Y]  - MAGNUSDOTTIR et al., "Systematic genome assessment uf B-vitamin biosynthesis suggests co-operation among gut microbes", Frontiers in Genetics, (20150420), vol. 6, no. 148, pages 1 - 18, XP055385258 [Y] 5-11, 22-25, 29-35, 43 * . entire document *

DOI:   http://dx.doi.org/10.3389/fgene.2015.00148
 [Y]  - VÉTIZOU et al., "Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota", Science, (20151105), vol. 350, no. 6264, pages 1079 - 1084, XP055310374 [Y] 18-25, 40 * . entire document *

DOI:   http://dx.doi.org/10.1126/science.aad1329
by applicantUS2015238544
 WO2015166492
    - VETIZOU et al., Science, (20150000), vol. 350, no. 6264, pages 1079 - 1084
    - KRONKREPPEL, CURR, Gene Ther, (20120000), vol. 12, no. 5, pages 362 - 73
    - YI et al., Curr Gene Ther, (20110000), vol. 11, no. 3, pages 218 - 28
    - GOLDSPIEL et al., Clinical Pharmacy, (19930000), vol. 12, pages 488 - 505
    - WUWU, Biotherapy, (19910000), vol. 3, pages 87 - 95
    - TOLSTOSHEV, Ann. Rev. Pharmacol. Toxicol., (19930000), vol. 32, pages 573 - 596
    - MULLIGAN, Science, (19930000), vol. 260, pages 926 - 932
    - MORGANANDERSON, Ann. Rev. Biochem., (19930000), vol. 62, pages 191 - 217
    - MAY, TIBTECH, (19930000), vol. 11, no. 5, pages 155 - 215
    - COHEN et al., Meth. Enzymol., (19930000), vol. 217, pages 618 - 644
    - Cline, Pharmac. Ther., (19850000), vol. 29, pages 69 - 92
    - "NCBI SRA", Database accession no. PRJNA302832
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.